• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单克隆抗体识别一种与活化细胞癌基因相关的细胞表面抗原。

Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene.

作者信息

Drebin J A, Stern D F, Link V C, Weinberg R A, Greene M I

出版信息

Nature. 1984;312(5994):545-8. doi: 10.1038/312545a0.

DOI:10.1038/312545a0
PMID:6504162
Abstract

A variety of antigens have been identified on the surface of the malignant cell. However, identical antigens are often found on non-malignant cells of the same or different histological origin, or of a different stage of embryonic development. Many of these tumour-associated antigens appear to be only incidentally expressed on neoplastic cells. Clearly, it would be of great interest to identify cell-surface antigens whose expression is associated specifically with the transformed state and linked directly with the mechanisms responsible for transformation. The detection of activated cellular oncogenes in human and animal cancer cells by the technique of DNA transfection has allowed the isolation of genetic elements which are thought to have a critical role in malignancy. Here, in an effort to identify cell-surface antigens associated with the neoplastic process, we have generated hybridomas which secrete monoclonal antibodies that react specifically with cell-surface determinants found on NIH 3T3 cells transformed by transfection with a group of rat neuroblastoma oncogenes. These antibodies bind to and immunoprecipitate a phosphoprotein of relative molecular mass 185,000 (185 K) from a DNA donor rat neuroblastoma and 13 independent rat neuroblastoma DNA transfectants. There was no antibody reactivity with normal NIH 3T3 cells or with NIH 3T3 cells transformed by various other agents.

摘要

已在恶性细胞表面鉴定出多种抗原。然而,在相同或不同组织学来源、或处于胚胎发育不同阶段的非恶性细胞上,常常能发现相同的抗原。许多这类肿瘤相关抗原似乎只是偶然在肿瘤细胞上表达。显然,鉴定那些其表达与转化状态特异性相关且直接与转化机制相联系的细胞表面抗原,将会非常有意义。通过DNA转染技术在人和动物癌细胞中检测活化的细胞癌基因,已使得人们能够分离出被认为在恶性肿瘤中起关键作用的遗传元件。在此,为了鉴定与肿瘤形成过程相关的细胞表面抗原,我们制备了杂交瘤,这些杂交瘤分泌的单克隆抗体能与用一组大鼠神经母细胞瘤癌基因转染而转化的NIH 3T3细胞上发现的细胞表面决定簇发生特异性反应。这些抗体能结合并免疫沉淀来自DNA供体大鼠神经母细胞瘤和13个独立的大鼠神经母细胞瘤DNA转染细胞的相对分子质量为185,000(185K)的一种磷蛋白。正常NIH 3T3细胞或由其他各种因子转化的NIH 3T3细胞均无抗体反应性。

相似文献

1
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene.单克隆抗体识别一种与活化细胞癌基因相关的细胞表面抗原。
Nature. 1984;312(5994):545-8. doi: 10.1038/312545a0.
2
A novel approach to production of antitumor monoclonal antibodies: antibody to a cell surface glycoprotein associated with transformation by a human oncogene.
Surgery. 1984 Aug;96(2):264-72.
3
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.单克隆抗体对癌基因蛋白产物的下调作用及转化表型的逆转
Cell. 1985 Jul;41(3):697-706. doi: 10.1016/s0092-8674(85)80050-7.
4
Expression of Ly-6.2 and Thy-1 antigens on NIH 3T3 cells suppressed after transformation with activated human ras-oncogenes.
Int J Cancer. 1986 Oct 15;38(4):575-80. doi: 10.1002/ijc.2910380418.
5
[Expression of cell surface transformation-associated antigens TAAs on activated oncogene-transfected rat fibroblast and antitumor immunity by hosts].[细胞表面转化相关抗原TAAs在激活的癌基因转染大鼠成纤维细胞上的表达及宿主的抗肿瘤免疫]
Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):653-61.
6
Identification of transformation-related antigen by monoclonal antibody on Swiss 3T3 cells induced by transfection with murine cultured colon 36 tumor DNA.用小鼠培养的结肠36肿瘤DNA转染瑞士3T3细胞后,通过单克隆抗体鉴定转化相关抗原。
J Natl Cancer Inst. 1987 Feb;78(2):307-13.
7
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.大鼠神经母细胞瘤转化DNA特异性诱导的一种磷蛋白的鉴定。
Cell. 1982 Apr;28(4):865-71. doi: 10.1016/0092-8674(82)90065-4.
8
[Identification of the transforming Ha-ras gene in human melanoma, neuroblastoma and breast cancer cells].[人类黑色素瘤、神经母细胞瘤和乳腺癌细胞中转化型Ha-ras基因的鉴定]
Vopr Onkol. 1985;31(6):77-85.
9
Identification of the transformation-associated cell surface antigen expressed on the rat fetus-derived fibroblast.鉴定在大鼠胎儿来源的成纤维细胞上表达的转化相关细胞表面抗原。
Cancer Res. 1988 May 15;48(10):2798-804.
10
Tumor rejection antigens on BALB3T3 cells transformed by activated oncogenes.
J Immunol. 1991 Nov 1;147(9):3251-8.

引用本文的文献

1
HER2 testing: evolution and update for a companion diagnostic assay.人表皮生长因子受体2检测:伴随诊断检测的进展与更新
Nat Rev Clin Oncol. 2025 Apr 7. doi: 10.1038/s41571-025-01016-y.
2
Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development.靶向乳腺癌中的erbB通路:双重激酶抑制用于脑转移及预防p185HER2/Neu肿瘤发展
Breast Cancer (Dove Med Press). 2024 Oct 30;16:725-733. doi: 10.2147/BCTT.S490904. eCollection 2024.
3
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics.
HER2 在癌症生物学和治疗学中的全面综述。
Genes (Basel). 2024 Jul 11;15(7):903. doi: 10.3390/genes15070903.
4
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.系统给予低亲和力 HER2 CAR T 细胞可介导抗肿瘤疗效而无毒性。
J Immunother Cancer. 2024 Feb 7;12(2):e008566. doi: 10.1136/jitc-2023-008566.
5
Sequencing of N-methyl-deoxyadenosine at single-base resolution across the mammalian genome.单碱基分辨率下全哺乳动物基因组 N6-甲基脱氧腺苷测序。
Mol Cell. 2024 Feb 1;84(3):596-610.e6. doi: 10.1016/j.molcel.2023.12.021. Epub 2024 Jan 11.
6
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.晚期HER2阳性乳腺癌患者的管理:当前证据与未来展望
Nat Rev Clin Oncol. 2024 Mar;21(3):185-202. doi: 10.1038/s41571-023-00849-9. Epub 2024 Jan 8.
7
Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model.使用多样化远交系小鼠模型鉴定乳腺癌干预的可操作靶点。
iScience. 2023 Mar 2;26(4):106320. doi: 10.1016/j.isci.2023.106320. eCollection 2023 Apr 21.
8
Targeting HER2-positive breast cancer: advances and future directions.针对 HER2 阳性乳腺癌:进展与未来方向。
Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. Epub 2022 Nov 7.
9
PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.PARG 抑制肿瘤发生,并下调控制血管生成、炎症反应和免疫细胞募集的基因。
BMC Cancer. 2022 May 18;22(1):557. doi: 10.1186/s12885-022-09651-9.
10
Current status and future perspectives in HER2 positive advanced gastric cancer.HER2阳性晚期胃癌的现状与未来展望
Clin Transl Oncol. 2022 Jun;24(6):981-996. doi: 10.1007/s12094-021-02760-0. Epub 2022 Jan 29.